Medical Professionals Reference (MPR)Mounjaro Approved to Reduce MACE Risk in Adults with T2DM

📋 Regulatory Action / Label Change

The expanded indication adds cardiovascular risk reduction to tirzepatide’s established glycemic-control role. The approval applies to adults with type 2 diabetes at high cardiovascular risk.

Professional Impact

• SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and established cardiovascular disease.
• MACE-3 occurred in 12.1% with tirzepatide versus 13.0% with dulaglutide.
• Tirzepatide met noninferiority, with an HR of 0.92 and 95% CI of 0.83 to 1.01.
• All-cause mortality was 8.5% versus 10.1%, although this was not the primary endpoint.

Action Items

• Review the expanded indication when treating eligible adults with type 2 diabetes.
• Distinguish demonstrated noninferiority from an unproven claim of cardiovascular superiority.
• Evaluate gastrointestinal tolerability and individual contraindications before prescribing.
• Update formulary, counseling, and documentation materials to reflect the label expansion.